3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
28
Unknown
3
Withdrawn
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Triple Negative Breast Neoplasms
2
Neuroblastoma
2
Melanoma
2
Lung Neoplasms
2
Gliosarcoma
2
Glioblastoma
2
Unilateral Breast Neoplasms
1
Prostatic Neoplasms
1
Pathologic Complete Response
1
Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Mesothelioma, Malignant
1
Mesothelioma
1
Locally Advanced Pancreatic Adenocarcinoma
1
Leukemia, Plasma Cell
1
Leukemia, Myeloid, Acute
1
Inflammatory Breast Neoplasms
1
Ganglioneuroblastoma
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
Azacitidine
38
Cytarabine
37
venetoclax
34
fludarabine
28
Cyclophosphamide
21
Daunorubicin
18
fludarabine phosphate
17
Decitabine
16
Specimen Handling
15
Tacrolimus
14
Busulfan
13
Injections
12
Biopsy
12
Melphalan
11
Granulocyte Colony-Stimulating Factor
11
CPX-351
11
Mycophenolic Acid
10
Idarubicin
10
Stem Cell Transplantation
9
Whole-Body Irradiation
8
Etoposide
8
decitabine and cedazuridine drug combination
7
Thiotepa
7
Mitoxantrone
7
enasidenib
6
Peripheral Blood Stem Cell Transplantation
6
Methotrexate
6
ivosidenib
5
gilteritinib
5
Gemtuzumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Leukemia, Myeloid, Acute
×
sargramostim
×
Clear all
NCT04229979
2025-10-01
REGAL
Sellas Life Sciences Group
Phase 3
Active not recruiting
127 enrolled